Pharming Group N.V annual operating margin
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Operating Margin Growth & History (PHAR)
Pharming Group N.V's operating margin was 6.87% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 6.87% | +9.77 pp |
| 2024 | 2024-12-31 | −2.90% | −0.70 pp |
| 2023 | 2023-12-31 | −2.20% | −11.06 pp |
| 2022 | 2022-12-31 | 8.87% | +2.05 pp |
| 2021 | 2021-12-31 | 6.82% | −29.12 pp |
| 2020 | 2020-12-31 | 35.94% | −0.09 pp |
| 2019 | 2019-12-31 | 36.03% | — |
Pharming Group N.V quarterly operating margin
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −0.12% | −9.78 pp |
| Q1 2026 | 2026-03-31 | −7.30% | — |
| Q4 2025 | 2025-12-31 | 1.88% | — |
| Q3 2025 | 2025-09-30 | 16.19% | — |
| Q2 2025 | 2025-06-30 | 9.65% | — |
Pharming Group N.V operating margin trends
Over the last five fiscal years, Pharming Group N.V's operating margin decreased from 35.94% to 6.87%, a change of −29.07 percentage points. The latest reported quarter, Q2 2026, shows −0.12%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
